Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2015, Article ID 352356, 11 pages
http://dx.doi.org/10.1155/2015/352356
Research Article

Plasma Nitration of High-Density and Low-Density Lipoproteins in Chronic Kidney Disease Patients Receiving Kidney Transplants

1Department of Cell Biology, SUNY Downstate Medical Center, Brooklyn, NY, USA
2The Department of Veterans Affairs New York Harbor Healthcare System, Brooklyn, NY, USA
3Department of Medicine, SUNY Downstate Medical Center, Brooklyn, NY, USA
4Department of Surgery, SUNY Downstate Medical Center, Brooklyn, NY, USA

Received 19 May 2015; Revised 14 October 2015; Accepted 19 October 2015

Academic Editor: Aaron L. Sverdlov

Copyright © 2015 Ahmed Bakillah et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. G. Collins and D. Altman, “Predicting the risk of chronic kidney disease in the UK: an evaluation of QKidney scores using a primary care database,” British Journal of General Practice, vol. 62, no. 597, pp. e243–e250, 2012. View at Publisher · View at Google Scholar · View at Scopus
  2. T. I. Steinman, “The older patient with end-stage renal disease: is chronic dialysis the best option?” Seminars in Dialysis, vol. 25, no. 6, pp. 602–605, 2012. View at Publisher · View at Google Scholar · View at Scopus
  3. G. Giamouzis, A. P. Kalogeropoulos, J. Butler et al., “Epidemiology and importance of renal dysfunction in heart failure patients,” Current Heart Failure Reports, vol. 10, no. 4, pp. 411–420, 2013. View at Publisher · View at Google Scholar · View at Scopus
  4. R. J. Macisaac, E. I. Ekinci, and G. Jerums, “Markers of and risk factors for the development and progression of diabetic kidney disease,” American Journal of Kidney Diseases, vol. 63, supplement 2, no. 2, pp. S39–S62, 2014. View at Publisher · View at Google Scholar · View at Scopus
  5. N. S. Anavekar and M. A. Pfeffer, “Cardiovascular risk in chronic kidney disease,” Kidney International. Supplement, vol. 92, pp. S11–S15, 2004. View at Google Scholar · View at Scopus
  6. X.-C. Wu, B.-C. Liu, Y.-L. Wang et al., “Prevalence of chronic kidney disease in Chinese hospitalized adult patients: investigation of 13,383 cases,” Zhonghua Yi Xue Za Zhi, vol. 87, no. 38, pp. 2672–2676, 2007. View at Google Scholar · View at Scopus
  7. C. Baigent and M. Landry, “Study of heart and renal protection (SHARP),” Kidney International. Supplement, vol. 84, pp. S207–S210, 2003. View at Google Scholar
  8. S. C. Palmer, J. C. Craig, S. D. Navaneethan, M. Tonelli, F. Pellegrini, and G. F. M. Strippoli, “Benefits and harms of statin therapy for persons with chronic kidney disease: a systematic review and meta-analysis,” Annals of Internal Medicine, vol. 157, no. 4, pp. 263–275, 2012. View at Publisher · View at Google Scholar · View at Scopus
  9. C. Wanner and E. Ritz, “Reducing lipids for CV protection in CKD patients—current evidence,” Kidney International, vol. 74, no. 111, pp. S24–S28, 2008. View at Publisher · View at Google Scholar · View at Scopus
  10. B. Fellström, H. Holdaas, A. G. Jardine et al., “Cardiovascular disease in patients with renal disease: the role of statins,” Current Medical Research and Opinion, vol. 25, no. 1, pp. 271–285, 2009. View at Publisher · View at Google Scholar · View at Scopus
  11. E. Di Angelantonio, N. Sarwar, P. Perry et al., “Major lipids, apolipoproteins, and risk of vascular disease,” The Journal of the American Medical Association, vol. 302, no. 18, pp. 1993–2000, 2009. View at Publisher · View at Google Scholar · View at Scopus
  12. D. J. Rader, “Molecular regulation of HDL metabolism and function: implications for novel therapies,” Journal of Clinical Investigation, vol. 116, no. 12, pp. 3090–3100, 2006. View at Publisher · View at Google Scholar · View at Scopus
  13. P. J. Barter and C. L. Shear, “Aggressive management of obesity in children and young adults: the known challenges and potential opportunities,” Clinical Pharmacology and Therapeutics, vol. 81, no. 5, pp. 627–630, 2007. View at Publisher · View at Google Scholar · View at Scopus
  14. G. G. Schwartz, “New horizons for cholesterol ester transfer protein inhibitors,” Current Atherosclerosis Reports, vol. 14, no. 1, pp. 41–48, 2012. View at Publisher · View at Google Scholar · View at Scopus
  15. S. C. Gordts, N. Singh, I. Muthuramu, and B. de Geest, “Pleiotropic effects of HDL: towards new therapeutic areas for HDL-targeted interventions,” Current Molecular Medicine, vol. 14, no. 4, pp. 481–503, 2014. View at Publisher · View at Google Scholar · View at Scopus
  16. P. P. Toth, P. J. Barter, R. S. Rosenson et al., “High-density lipoproteins: a consensus statement from the National Lipid Association,” Journal of Clinical Lipidology, vol. 7, no. 5, pp. 484–525, 2013. View at Publisher · View at Google Scholar · View at Scopus
  17. K.-A. Rye and P. J. Barter, “Cardioprotective functions of HDLs,” Journal of Lipid Research, vol. 55, no. 2, pp. 168–179, 2014. View at Publisher · View at Google Scholar · View at Scopus
  18. R. K. Schindhelm, L. P. van der Zwan, T. Teerlink, and P. G. Scheffer, “Myeloperoxidase: a useful biomarker for cardiovascular disease risk stratification?” Clinical Chemistry, vol. 55, no. 8, pp. 1462–1470, 2009. View at Publisher · View at Google Scholar · View at Scopus
  19. B. Pan, B. Yu, H. Ren et al., “High-density lipoprotein nitration and chlorination catalyzed by myeloperoxidase impair its effect of promoting endothelial repair,” Free Radical Biology and Medicine, vol. 60, pp. 272–281, 2013. View at Publisher · View at Google Scholar · View at Scopus
  20. E. Ho, K. Karimi Galougahi, C.-C. Liu, R. Bhindi, and G. A. Figtree, “Biological markers of oxidative stress: applications to cardiovascular research and practice,” Redox Biology, vol. 1, no. 1, pp. 483–491, 2013. View at Publisher · View at Google Scholar · View at Scopus
  21. L. Zheng, B. Nukuna, M.-L. Brennan et al., “Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease,” Journal of Clinical Investigation, vol. 114, no. 4, pp. 529–541, 2004. View at Publisher · View at Google Scholar · View at Scopus
  22. K. A. Hadfield, D. I. Pattison, B. E. Brown et al., “Myeloperoxidase-derived oxidants modify apolipoprotein A-I and generate dysfunctional high-density lipoproteins: comparison of hypothiocyanous acid (HOSCN) with hypochlorous acid (HOCl),” Biochemical Journal, vol. 449, no. 2, pp. 531–542, 2013. View at Publisher · View at Google Scholar · View at Scopus
  23. Y. Huang, J. A. Didonato, B. S. Levison et al., “An abundant dysfunctional apolipoprotein A1 in human atheroma,” Nature Medicine, vol. 20, no. 2, pp. 193–203, 2014. View at Publisher · View at Google Scholar · View at Scopus
  24. I. H. de Boer and J. D. Brunzell, “HDL in CKD: how good is the ‘good cholesterol?’,” Journal of the American Society of Nephrology, vol. 25, no. 5, pp. 871–874, 2014. View at Publisher · View at Google Scholar · View at Scopus
  25. H. Moradi, M. V. Pahl, R. Elahimehr, and N. D. Vaziri, “Impaired antioxidant activity of high-density lipoprotein in chronic kidney disease,” Translational Research, vol. 153, no. 2, pp. 77–85, 2009. View at Publisher · View at Google Scholar · View at Scopus
  26. N. D. Vaziri, “Lipotoxicity and impaired high density lipoprotein-mediated reverse cholesterol transport in chronic kidney disease,” Journal of Renal Nutrition, vol. 20, no. 5, supplement, pp. S35–S43, 2010. View at Publisher · View at Google Scholar · View at Scopus
  27. W. H. F. Sutherland, J. Corboy, R. J. Walker, M. C. Robertson, and M. J. Ball, “Cell cholesterol transport to plasma in blood from patients with renal failure or a kidney transplant,” Nephrology Dialysis Transplantation, vol. 10, no. 3, pp. 358–365, 1995. View at Google Scholar · View at Scopus
  28. R. Kaseda, K. Jabs, T. E. Hunley et al., “Dysfunctional high-density lipoproteins in children with chronic kidney disease,” Metabolism, vol. 64, no. 2, pp. 263–273, 2015. View at Publisher · View at Google Scholar · View at Scopus
  29. A. Baragetti, G. D. Norata, C. Sarcina et al., “High density lipoprotein cholesterol levels are an independent predictor of the progression of chronic kidney disease,” Journal of Internal Medicine, vol. 274, no. 3, pp. 252–262, 2013. View at Publisher · View at Google Scholar · View at Scopus
  30. G. Guilgen, M. L. Werneck, L. de Noronha et al., “Increased calcification and protein nitration in arteries of chronic kidney disease patients,” Blood Purification, vol. 32, no. 4, pp. 296–302, 2011. View at Publisher · View at Google Scholar · View at Scopus
  31. M. Piroddi, A. Palmese, F. Pilolli et al., “Plasma nitroproteome of kidney disease patients,” Amino Acids, vol. 40, no. 2, pp. 653–667, 2011. View at Publisher · View at Google Scholar · View at Scopus
  32. S. Pennathur, C. Bergt, B. Shao et al., “Human atherosclerotic intima and blood of patients with established coronary artery disease contain high density lipoprotein damaged by reactive nitrogen species,” The Journal of Biological Chemistry, vol. 279, no. 41, pp. 42977–42983, 2004. View at Publisher · View at Google Scholar · View at Scopus
  33. B. Shao, C. Bergt, X. Fu et al., “Tyrosine 192 in apolipoprotein A-I is the major site of nitration and chlorination by myeloperoxidase, but only chlorination markedly impairs ABCA1-dependent cholesterol transport,” The Journal of Biological Chemistry, vol. 280, no. 7, pp. 5983–5993, 2005. View at Publisher · View at Google Scholar · View at Scopus
  34. A. Bakillah, “Nitrated apolipoprotein A-I, a potential new cardiovascular marker, is markedly increased in low high-density lipoprotein cholesterol subjects,” Clinical Chemistry and Laboratory Medicine, vol. 47, no. 1, pp. 60–69, 2009. View at Publisher · View at Google Scholar · View at Scopus
  35. E. Vazquez, A. A. Sethi, L. Freeman et al., “High-density lipoprotein cholesterol efflux, nitration of apolipoprotein A-I, and endothelial function in obese women,” The American Journal of Cardiology, vol. 109, no. 4, pp. 527–532, 2012. View at Publisher · View at Google Scholar · View at Scopus
  36. O. Hasselwander, J. McEneny, D. McMaster et al., “HDL composition and HDL antioxidant capacity in patients on regular haemodialysis,” Atherosclerosis, vol. 143, no. 1, pp. 125–133, 1999. View at Publisher · View at Google Scholar · View at Scopus
  37. M. M. Hussain, Y. Zhao, R. K. Kancha, B. D. Blackhart, and Z. Yao, “Characterization of recombinant human ApoB-48-containing lipoproteins in rat hepatoma McA-RH7777 cells transfected with ApoB-48 cDNA: overexpression of ApoB-48 decreases synthesis of endogenous ApoB-100,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 15, no. 4, pp. 485–494, 1995. View at Publisher · View at Google Scholar · View at Scopus
  38. A. Bakillah, Z. Zhou, J. Luchoomun, and M. M. Hussain, “Measurement of apolipoprotein B in various cell lines: correlation between intracellular levels and rates of secretion,” Lipids, vol. 32, no. 10, pp. 1113–1118, 1997. View at Publisher · View at Google Scholar · View at Scopus
  39. K. D. Navab, O. Elboudwarej, M. Gharif et al., “Chronic inflammatory disorders and accelerated atherosclerosis: chronic kidney disease,” Current Pharmaceutical Design, vol. 17, no. 1, pp. 17–20, 2011. View at Google Scholar
  40. G. Khoueiry, M. Abdallah, F. Saiful et al., “High-density lipoprotein in uremic patients: metabolism, impairment, and therapy,” International Urology and Nephrology, vol. 46, no. 1, pp. 27–39, 2014. View at Publisher · View at Google Scholar · View at Scopus
  41. N. Singh, F. Jacobs, D. J. Rader, J. Vanhaecke, J. Van Cleemput, and B. De Geest, “Impaired cholesterol efflux capacity and vasculoprotective function of high-density lipoprotein in heart transplant recipients,” Journal of Heart and Lung Transplantation, vol. 33, no. 5, pp. 499–506, 2014. View at Publisher · View at Google Scholar · View at Scopus
  42. G. A. Kaysen, “Lipid and lipoprotein metabolism in chronic kidney disease,” Journal of Renal Nutrition, vol. 19, no. 1, pp. 73–77, 2009. View at Publisher · View at Google Scholar · View at Scopus
  43. H. R. Griffiths, S. Aldred, C. Dale et al., “Homocysteine from endothelial cells promotes LDL nitration and scavenger receptor uptake,” Free Radical Biology and Medicine, vol. 40, no. 3, pp. 488–500, 2006. View at Publisher · View at Google Scholar · View at Scopus
  44. R. Zhang, M.-L. Brennan, X. Fu et al., “Association between myeloperoxidase levels and risk of coronary artery disease,” Journal of the American Medical Association, vol. 286, no. 17, pp. 2136–2142, 2001. View at Publisher · View at Google Scholar · View at Scopus
  45. E. Cavusoglu, C. Ruwende, C. Eng et al., “Usefulness of baseline plasma myeloperoxidase levels as an independent predictor of myocardial infarction at two years in patients presenting with acute coronary syndrome,” American Journal of Cardiology, vol. 99, no. 10, pp. 1364–1368, 2007. View at Publisher · View at Google Scholar · View at Scopus
  46. B. Shao, S. Pennathur, and J. W. Heinecke, “Myeloperoxidase targets apolipoprotein A-I, the major high density lipoprotein protein, for site-specific oxidation in human atherosclerotic lesions,” Journal of Biological Chemistry, vol. 287, no. 9, pp. 6375–6386, 2012. View at Publisher · View at Google Scholar · View at Scopus
  47. T. K. Hsiai, J. Hwang, M. L. Barr et al., “Hemodynamics influences vascular peroxynitrite formation: implication for low-density lipoprotein apo-B-100 nitration,” Free Radical Biology and Medicine, vol. 42, no. 4, pp. 519–529, 2007. View at Publisher · View at Google Scholar · View at Scopus
  48. R. T. Hamilton, L. Asatryan, J. T. Nilsen et al., “LDL protein nitration: implication for LDL protein unfolding,” Archives of Biochemistry and Biophysics, vol. 479, no. 1, pp. 1–14, 2008. View at Publisher · View at Google Scholar · View at Scopus
  49. G. Ndrepepa, S. Braun, A. Schömig, and A. Kastrati, “Impact of therapy with statins, beta-blockers and angiotensin-converting enzyme inhibitors on plasma myeloperoxidase in patients with coronary artery disease,” Clinical Research in Cardiology, vol. 100, no. 4, pp. 327–333, 2011. View at Publisher · View at Google Scholar · View at Scopus
  50. A. Lehners, S. Lange, G. Niemann et al., “Myeloperoxidase deficiency ameliorates progression of chronic kidney disease in mice,” The American Journal of Physiology—Renal Physiology, vol. 307, no. 4, pp. F407–F417, 2014. View at Publisher · View at Google Scholar · View at Scopus
  51. A. Madhusudhana Rao, U. Anand, and C. V. Anand, “Myeloperoxidase in chronic kidney disease,” Indian Journal of Clinical Biochemistry, vol. 26, no. 1, pp. 28–31, 2011. View at Publisher · View at Google Scholar · View at Scopus
  52. C.-H. Guo and C.-L. Wang, “Plasma aluminum is a risk factor for oxidative stress and inflammation status in hemodialysis patients,” Clinical Biochemistry, vol. 44, no. 16, pp. 1309–1314, 2011. View at Publisher · View at Google Scholar · View at Scopus
  53. J. Vostálová, A. Galandáková, A. R. Svobodová et al., “Time-course evaluation of oxidative stress-related biomarkers after renal transplantation,” Renal Failure, vol. 34, no. 4, pp. 413–419, 2012. View at Publisher · View at Google Scholar · View at Scopus
  54. V. Costa-Hong, L. A. Bortolotto, V. Jorgetti, F. Consolim-Colombo, E. M. Krieger, and J. J. G. De Lima, “Oxidative stress and endothelial dysfunction in chronic kidney disease,” Arquivos Brasileiros de Cardiologia, vol. 92, no. 5, pp. 413–418, 2009. View at Google Scholar · View at Scopus
  55. C. Capusa, I. Stoian, E. Rus, D. Lixandru, C. Barbulescu, and G. Mircescu, “Does dialysis modality influence the oxidative stress of uremic patients?” Kidney and Blood Pressure Research, vol. 35, no. 4, pp. 220–225, 2012. View at Publisher · View at Google Scholar · View at Scopus
  56. K. J. Moore and E. A. Fisher, “Dysfunctional hdl takes its toll in chronic kidney disease,” Immunity, vol. 38, no. 4, pp. 628–630, 2013. View at Publisher · View at Google Scholar · View at Scopus
  57. G. A. Spinelli, C. R. Felipe, S. I. Park, E. L. Mandia-Sampaio, H. Tedesco-Silva Jr., and J. O. Medina-Pestana, “Lipid profile changes during the first year after kidney transplantation: risk factors and influence of the immunosuppressive drug regimen,” Transplantation Proceedings, vol. 43, no. 10, pp. 3730–3737, 2011. View at Publisher · View at Google Scholar · View at Scopus